Medical devices, healthcare technology and the business of care
510(k) clearance · K261783

Plenity-V (MC0979 / GS110)

Gelesis SRL · Decision date Oct 2, 2026

MEDTECHLEDGER EXPLANATIONK261783

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision for K261783, Plenity-V (MC0979/GS110), on October 2, 2026, with the applicant listed as Gelesis SRL and product code QFQ under 21 CFR 876.5982. The submission is a traditional 510(k), so the decision is a clearance rather than a PMA approval. The summary describes Plenity-V as identical to the cleared predicate Plenity (K230133) in technological characteristics and mechanism of action, with the change limited to the capsule: a transparent HPMC capsule of the same size replaces the white porcine gelatin capsule.

The stated rationale is that the change replaces an animal-derived component with a plant-based material and removes titanium dioxide, and the summary reports no nonclinical or bench studies conducted specifically for the capsule material change. The summary also states that stability work was performed on Plenity pods with a comparison said to apply to Plenity-V blisters, and that a multi-lot Plenity-V stability study is ongoing to confirm a 30-month shelf life. The source does not provide the review basis for the decision or independent confirmation of the sponsor's equivalence and safety statements.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Gastroenterology, Urology
Decision date
Oct 2, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K261783
Regulatory pathway
510(k) premarket notification
Applicant
Gelesis SRL
Product code
QFQ
Decision code
SESE
Decision date
Oct 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Ingested, Transient, Space Occupying Device For Weight Management And/Or Weight Loss.

Applicant
Gelesis SRL
Product code
QFQ
FDA device class
2

FDA decision timeline

  1. K261783 received

    Application receipt date recorded by FDA.

  2. K261783 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Gelesis SRL

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Calimera

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records